10x Genomics, Inc. (TXG) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific.
Is 10x Genomics, Inc. stock overvalued or undervalued in 2026?
As of October 2, 2026, 10x Genomics, Inc. (TXG) trades at $90.04 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: 10x Genomics, Inc.
Market cap $11B · 52 weeks $11 – $98 (0 % below the high) · P/E no earnings · Dividend none · Next earnings November 5, 2026 · expected EPS $-0.27 · Price as of Oct 2 · accounts published Aug 6.
- Valuation: P/Sales 5.2× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 6 of 8 (on track).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 2.1 %, fails.
- Market cap / Cash 21.5×, fails.
- Annual cash burn $1.09, passes.
- Total Debt 0.3×, passes.
Against its peers (reference peers) — 10x Genomics, Inc.: P/E —; EV/EBITDA —; ROIC -9.6 %; $11.4B. Guardian Pharmacy Services, Inc. (P/E 40.4×; EV/EBITDA 19.2×; ROIC 22.9 %; $2.7B), Bio-Techne Corporation (P/E 62.4×; EV/EBITDA 32.1×; ROIC 7.5 %; $11.3B), Halozyme Therapeutics, Inc. (P/E 31.2×; EV/EBITDA 20.8×; ROIC 27.4 %; $12.7B).
Profitability
| Return on Equity | -9.33% |
| Return on Invested Capital | -9.57% |
| Return on Assets | -7.29% |
| Gross Margin | 70.03% |
| Operating Margin | -14.33% |
| Net Margin | -12.18% |
Financial Health
| Debt / Equity | 0.10 |
| Current Ratio | 5.69 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 3.83 |
Price Performance
| 1 month | +56.01% |
| 3 months | +160.85% |
| Year-to-date | +499.26% |
| 1 year | +673.26% |
| 3 years | +152.75% |
| 5 years | -36.54% |
Related companies: CERT · GRDN · JANX · NUVB · OMCL · OMDA · PGNY
Explore sector: Healthcare · Biotechnology
More sections of TXG: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks